Fiche publication
Date publication
août 2020
Journal
Scientific reports
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BENKIRANE-JESSEL Nadia
,
Dr DESAUBRY Laurent
,
Dr DONTENWILL Monique
,
Dr MASSFELDER Thierry
,
Pr GRANDEMANGE Stéphanie
,
Dr IDOUX-GILLET Ysia
,
Dr FIORETTI Florence
,
Pr UBEAUD-SEQUIER Genevieve
,
Dr FUHRMANN Guy
Tous les auteurs :
Harmouch E, Seitlinger J, Chaddad H, Ubeaud-Sequier G, Barths J, Saidu S, Désaubry L, Grandemange S, Massfelder T, Fuhrmann G, Fioretti F, Dontenwill M, Benkirane-Jessel N, Idoux-Gillet Y
Lien Pubmed
Résumé
Glioblastoma (GBM) is one of the most aggressive types of cancer, which begins within the brain. It is the most invasive type of glioma developed from astrocytes. Until today, Temozolomide (TMZ) is the only standard chemotherapy for patients with GBM. Even though chemotherapy extends the survival of patients, there are many undesirable side effects, and most cases show resistance to TMZ. FL3 is a synthetic flavagline which displays potent anticancer activities, and is known to inhibit cell proliferation, by provoking cell cycle arrest, and leads to apoptosis in a lot of cancer cell lines. However, the effect of FL3 in glioblastoma cancer cells has not yet been examined. Hypoxia is a major problem for patients with GBM, resulting in tumor resistance and aggressiveness. In this study, we explore the effect of FL3 in glioblastoma cells under normoxia and hypoxia conditions. Our results clearly indicate that this synthetic flavagline inhibits cell proliferation and induced senescence in glioblastoma cells cultured under both conditions. In addition, FL3 treatment had no effect on human brain astrocytes. These findings support the notion that the FL3 molecule could be used in combination with other chemotherapeutic agents or other therapies in glioblastoma treatments.
Référence
Sci Rep. 2020 Aug 13;10(1):13750
